InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | 2026-03-12 | Culley Brian M | Director & President and CEO | Purchase | 15.0K | $1.63 | $24K | 255.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $947K-29.9% | $1.4M-0.5% | $1.4M+1.6% | $1.3M-69.2% | $4.3M |
| Cost of royalties | $146K-56.3% | $334K | — | — | — |
| Research and development | $17.7M+42.2% | $12.5M-20.6% | $15.7M+12.3% | $14.0M-58.8% | $33.9M |
| General and administrative | $18.5M+1.6% | $18.2M+5.0% | $17.3M-23.1% | $22.5M+23.6% | $18.2M |
| Loss on impairment of intangible asset (Note 6 and Note 13) | $14.8M | $0 | — | — | — |
| Total operating expenses | $51.2M+65.2% | $31.0M-8.0% | $33.7M-7.7% | $36.5M-30.0% | $52.1M |
| Loss from operations | -$36.6M-70.5% | -$21.5M+13.2% | -$24.7M-9.8% | -$22.5M+54.2% | -$49.2M |
| Interest income, net | $1.7M-1.4% | $1.7M+5.3% | $1.6M+96.5% | $829K+41350.0% | $2K |
| Loss on marketable equity securities, net | -$8K+0.0% | -$8K+95.5% | -$176K+92.0% | -$2.2M | — |
| Change in fair value of warrant liability | -$35.7M-1778.9% | $2.1M | $0-100.0% | $225K | — |
| Foreign currency transaction gain (loss), net | $2.1M+898.5% | -$269K+50.6% | -$544K | — | — |
| Other income (expense), net | -$132K+80.3% | -$670K-223.6% | $542K+125.2% | -$2.2M-244.8% | $1.5M |
| Total other income (expenses) | -$32.0M-1205.9% | $2.9M+99.6% | $1.5M+144.1% | -$3.3M-155.4% | $5.9M |
| LOSS BEFORE INCOME TAXES | -$68.6M-269.4% | -$18.6M+20.2% | -$23.3M+9.8% | -$25.8M+40.3% | -$43.3M |
| Income tax benefit | $5.3M | $0-100.0% | $1.8M+433.3% | -$541K | — |
| NET LOSS | -$63.4M-241.0% | -$18.6M+13.5% | -$21.5M+18.5% | -$26.4M+39.1% | -$43.3M |
| Net (income) loss attributable to noncontrolling interest | -$166K-514.8% | -$27K-285.7% | -$7K-108.7% | $80K-68.1% | $251K |
| NET LOSS ATTRIBUTABLE TO LINEAGE | -$63.5M-241.4% | -$18.6M+13.4% | -$21.5M+18.2% | -$26.3M+38.9% | -$43.0M |
| Net loss per common share attributable to Lineage basic | -$280-211.1% | -$90+25.0% | -$120+20.0% | -$150+42.3% | -$260 |
| Net loss per common share attributable to Lineage diluted | -$280-211.1% | -$90+25.0% | -$120+20.0% | -$150 | — |
| Weighted-average common shares used to compute net loss per common share, basic | $230.1M+14.9% | $200.2M+15.9% | $172.7M+1.7% | $169.8M+3.2% | $164.5M |
| Weighted-average common shares used to compute net loss per common share, diluted | $230.1M+14.9% | $200.2M+15.9% | $172.7M+1.7% | $169.8M | — |
| Collaboration Revenues [Member] | |||||
| Royalties, License and Other Revenues [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Promising Penny Stocks To Consider In May 2026
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing